Developer docs
API playgroundTry for free, no card

Search company profiles

US Compounding

Full company profile

uuid000skzx

Namestring
US Compounding
Company typeenum
Private
Founded yearint
2004
Descriptiontext

US Compounding, Inc. ("USC") is a privately held, for-profit drug compounding outsourcing facility registered with the U.S. Food and Drug Administration under Section 503B of the Federal Food, Drug, and Cosmetic Act. Founded in 2004 and headquartered in Conway, United States, USC manufactures sterile compounded preparations (such as injectables and other ready-to-administer dosages) for healthcare institutions, supplying hospitals, clinics, and other licensed providers that need regulatory-grade compounded medications that are not commercially available from traditional pharmaceutical manufacturers. As a 503B outsourcing facility, USC is required to operate under current Good Manufacturing Practice (cGMP) standards and is subject to direct FDA inspection, which distinguishes it from traditional 503A state-licensed compounding pharmacies.

The company employs 51-100 people and generates revenue through B2B supply arrangements with healthcare institutions, typically structured around per-unit pricing of compounded sterile preparations, with demand drivers including drug shortages, product discontinuation, and patient-specific clinical needs. Its customer base is institutional rather than retail, and its geographic footprint serves the U.S. market from its Conway base. Publicly disclosed information on pricing specifics, customer mix, exact product portfolio, regulatory certifications beyond 503B registration, leadership team, partnerships, and financial performance is not present in the provided data, which constrains deeper analysis of revenue mechanics, customer economics, and competitive positioning.

The 503B outsourcing facility segment is a small, regulated niche within U.S. pharmaceutical services, populated by a limited number of FDA-registered outsourcers. USC's two-decade operating history suggests an established position, but absent headcount trend, capital structure, product line, and revenue disclosures, the company's current scale, growth pace, and competitive standing relative to other 503B outsourcers cannot be quantified from the available evidence.

Short descriptiontext

US Compounding, Inc. is a privately held FDA-registered 503B drug compounding outsourcing facility founded in 2004 in Conway, United States, producing sterile compounded medications for U.S. hospitals, clinics, and licensed healthcare providers under cGMP standards.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersConway, United States
HQ citystring
Conway
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
compounding pharmacy services, outsourcing facility drugs, sterile pharmaceutical compounding, custom medication preparation, 503B compounding pharmacy
Industry1 code
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Compounding Pharmacy / Pharmaceutical Manufacturing
Social media profiles1 record
Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

US Compounding, Inc. (USC) is a privately held drug compounding outsourcing facility that prepares and supplies custom compounded pharmaceutical preparations, including sterile and non-sterile compounded medications, for licensed healthcare providers and patients. Operating as a registered outsourcing facility, USC produces quality-controlled compounded drug preparations under pharmaceutical manufacturing standards.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Compounded pharmaceutical preparations (outsourcing facility)
CategoryCompounding Pharmacy / Pharmaceutical Manufacturing
Description

Custom compounded drug preparations (sterile and non-sterile), produced under outsourcing-facility quality standards and supplied to licensed U.S. healthcare providers (hospitals, clinics, physician offices) and patients requiring medications not commercially available in the required form or quantity.

No data
Peers10 records
TypeDirect peer
Description

503A/503B-registered outsourcing compounder serving clinics and hospitals with sterile and non-sterile preparations; comparable in scale and customer mix to a privately-held regional outsourcing facility.

TypeDirect peer
Description

One of the largest FDA-registered 503B outsourcing facilities in the U.S., producing sterile and non-sterile compounded preparations for hospitals, clinics, and patients — directly comparable in regulatory category and product mix to US Compounding.

TypeDirect peer
Description

A large-scale FDA-registered 503B sterile compounding outsourcing facility serving hospitals and health systems nationwide. Closest competitor profile to US Compounding in terms of cGMP-compliant outsourcing manufacturing.

TypeDirect peer
Description

FDA-registered 503B outsourcing facility specializing in sterile admixture and ophthalmic preparations for hospital systems. Comparable outsourcing-facility business model and sterile compounding focus.

TypeDirect peer
Description

503B-registered outsourcing compounder producing sterile injectable and non-sterile preparations for hospitals; serves the same provider customer base with overlapping regulatory and product scope.

6Wedgewood Pharmacy
TypeDirect peer
Description

Large specialty compounding pharmacy producing both sterile and non-sterile preparations for human and veterinary providers; similar compounding-centric operating model though stronger on the animal-health side.

TypeBroad incumbent
Description

The largest hospital-focused sterile admixture outsourcing network in the U.S., owned by B. Braun. Comparable 503B outsourcing model but at substantially larger national scale, representing the upper bound of competitive intensity.

TypeBroad incumbent
Description

Specialty pharmacy with significant compounding capability serving providers and payors; overlaps with US Compounding on compounded products but operates a broader specialty-pharmacy portfolio.

TypeBroad incumbent
Description

Global leader in pharmaceutical compounding supplies and operator of compounding pharmacies; while a competitor on the services side, its primary scale comes from supplying APIs and bases to compounders like US Compounding.

10PCCA (Professional Compounding Centers of America)
TypeOthers
Description

Supplier of APIs, bases, equipment, and training to compounding pharmacies including US Compounding-type operations; not a direct service competitor but an ecosystem participant that defines the supply landscape.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

US Compounding

Compounding Pharmacy / Pharmaceutical Manufacturinguscompounding.com

US Compounding, Inc. is a privately held FDA-registered 503B drug compounding outsourcing facility founded in 2004 in Conway, United States, producing sterile compounded medications for U.S. hospitals, clinics, and licensed healthcare providers under cGMP standards.

What US Compounding does

US Compounding, Inc. ("USC") is a privately held, for-profit drug compounding outsourcing facility registered with the U.S. Food and Drug Administration under Section 503B of the Federal Food, Drug, and Cosmetic Act. Founded in 2004 and headquartered in Conway, United States, USC manufactures sterile compounded preparations (such as injectables and other ready-to-administer dosages) for healthcare institutions, supplying hospitals, clinics, and other licensed providers that need regulatory-grade compounded medications that are not commercially available from traditional pharmaceutical manufacturers. As a 503B outsourcing facility, USC is required to operate under current Good Manufacturing Practice (cGMP) standards and is subject to direct FDA inspection, which distinguishes it from traditional 503A state-licensed compounding pharmacies.

The company employs 51-100 people and generates revenue through B2B supply arrangements with healthcare institutions, typically structured around per-unit pricing of compounded sterile preparations, with demand drivers including drug shortages, product discontinuation, and patient-specific clinical needs. Its customer base is institutional rather than retail, and its geographic footprint serves the U.S. market from its Conway base. Publicly disclosed information on pricing specifics, customer mix, exact product portfolio, regulatory certifications beyond 503B registration, leadership team, partnerships, and financial performance is not present in the provided data, which constrains deeper analysis of revenue mechanics, customer economics, and competitive positioning.

The 503B outsourcing facility segment is a small, regulated niche within U.S. pharmaceutical services, populated by a limited number of FDA-registered outsourcers. USC's two-decade operating history suggests an established position, but absent headcount trend, capital structure, product line, and revenue disclosures, the company's current scale, growth pace, and competitive standing relative to other 503B outsourcers cannot be quantified from the available evidence.

US Compounding firmographics

Firmographics
Name
US Compounding
Website
https://uscompounding.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
51–100 employees
Short description
US Compounding, Inc. is a privately held FDA-registered 503B drug compounding outsourcing facility founded in 2004 in Conway, United States, producing sterile compounded medications for U.S. hospitals, clinics, and licensed healthcare providers under cGMP standards.
Ownership category
akta.pro rank

US Compounding industry classification

Industry
Product category
Compounding Pharmacy / Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

Keywords

  • Compounding pharmacy services
  • Outsourcing facility drugs
  • Sterile pharmaceutical compounding
  • Custom medication preparation
  • 503B compounding pharmacy

Where US Compounding is headquartered

Location

Headquarters

HQ city
Conway
HQ country
United States
HQ region
North America

Markets served

US Compounding business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

US Compounding product offering

Product offering

Core offering

US Compounding, Inc. (USC) is a privately held drug compounding outsourcing facility that prepares and supplies custom compounded pharmaceutical preparations, including sterile and non-sterile compounded medications, for licensed healthcare providers and patients. Operating as a registered outsourcing facility, USC produces quality-controlled compounded drug preparations under pharmaceutical manufacturing standards.

Differentiator

Problem solved

Functional benefit

Products and services

  • Compounded pharmaceutical preparations (outsourcing facility) Custom compounded drug preparations (sterile and non-sterile), produced under outsourcing-facility quality standards and supplied to licensed U.S. healthcare providers (hospitals, clinics, physician offices) and patients requiring medications not commercially available in the required form or quantity.

Companies that use US Compounding

Customer profile

Ideal customer profiles1 record

US Compounding technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

US Compounding competitors and assessment

Company assessment

Direct peers

  • McGuff Compounding Pharmacy Services: 503A/503B-registered outsourcing compounder serving clinics and hospitals with sterile and non-sterile preparations; comparable in scale and customer mix to a privately-held regional outsourcing facility.
  • Empower Pharmacy: One of the largest FDA-registered 503B outsourcing facilities in the U.S., producing sterile and non-sterile compounded preparations for hospitals, clinics, and patients — directly comparable in regulatory category and product mix to US Compounding.
  • QuVa Pharma: A large-scale FDA-registered 503B sterile compounding outsourcing facility serving hospitals and health systems nationwide. Closest competitor profile to US Compounding in terms of cGMP-compliant outsourcing manufacturing.
  • Leiters (Leiters Health): FDA-registered 503B outsourcing facility specializing in sterile admixture and ophthalmic preparations for hospital systems. Comparable outsourcing-facility business model and sterile compounding focus.
  • SCA Pharmaceuticals: 503B-registered outsourcing compounder producing sterile injectable and non-sterile preparations for hospitals; serves the same provider customer base with overlapping regulatory and product scope.
  • Wedgewood Pharmacy: Large specialty compounding pharmacy producing both sterile and non-sterile preparations for human and veterinary providers; similar compounding-centric operating model though stronger on the animal-health side.

Broad incumbents

  • Central Admixture Pharmacy Services (CAPS): The largest hospital-focused sterile admixture outsourcing network in the U.S., owned by B. Braun. Comparable 503B outsourcing model but at substantially larger national scale, representing the upper bound of competitive intensity.
  • Avella Specialty Pharmacy: Specialty pharmacy with significant compounding capability serving providers and payors; overlaps with US Compounding on compounded products but operates a broader specialty-pharmacy portfolio.
  • Fagron: Global leader in pharmaceutical compounding supplies and operator of compounding pharmacies; while a competitor on the services side, its primary scale comes from supplying APIs and bases to compounders like US Compounding.

Others

  • PCCA (Professional Compounding Centers of America): Supplier of APIs, bases, equipment, and training to compounding pharmacies including US Compounding-type operations; not a direct service competitor but an ecosystem participant that defines the supply landscape.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

US Compounding social profiles

Digital presence

US Compounding financial estimates

Financial estimate

Revenue estimate

Valuation estimate

US Compounding leadership team

Management profile

Number of profiles

US Compounding funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

US Compounding M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about US Compounding

What does US Compounding do?

US Compounding, Inc. (USC) is a privately held drug compounding outsourcing facility that prepares and supplies custom compounded pharmaceutical preparations, including sterile and non-sterile compounded medications, for licensed healthcare providers and patients. Operating as a registered outsourcing facility, USC produces quality-controlled compounded drug preparations under pharmaceutical manufacturing standards.

When was US Compounding founded?

US Compounding was founded in 2004. It employs 51 to 100 people.

Where is US Compounding based?

US Compounding is headquartered in Conway, United States, in the North America region.

Who are US Compounding's main competitors?

Direct peers on record are McGuff Compounding Pharmacy Services, Empower Pharmacy, QuVa Pharma, Leiters (Leiters Health), SCA Pharmaceuticals and Wedgewood Pharmacy. Broad incumbents are Central Admixture Pharmacy Services (CAPS), Avella Specialty Pharmacy and Fagron. PCCA (Professional Compounding Centers of America) is listed as an others.

Does US Compounding have an API?

No public API is recorded for US Compounding.

What industry is US Compounding in?

US Compounding's product category is Compounding Pharmacy / Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile). Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAdamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 PandemicAdamis Pharmaceuticals announced its subsidiary US Compounding Inc. shifted production to make medical-grade hand sanitizers for hospitals and health care workers amid the COVID-19 pandemic. The first batches will be shipped to hospitals in New York, which has been heavily impacted. The company will continue manufacturing as long as there is a shortage.GlobeNewswireAdamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business UpdateAdamis Pharmaceuticals reported Q1 2019 revenue of $4.9 million, up 53% year-over-year, driven by US Compounding and SYMJEPI sales. The company expects SYMJEPI retail launch and FDA approval of its naloxone product by October 31, 2019.GlobeNewswireAdamis Pharmaceuticals Announces 2018 Financial Results and Provides Business UpdateAdamis Pharmaceuticals reported 2018 revenues of $15.1 million, up from $13.1 million in 2017, with SG&A and R&D expenses rising. The company highlighted FDA approvals for SYMJEPI 0.15mg and an NDA for higher-dose naloxone, while US Compounding revenue grew 15% but missed its growth target.GlobeNewswireUS Compounding, a Subsidiary of Adamis Pharmaceuticals, Develops a Unique Compound to Manage Ulcers in HorsesUS Compounding, a subsidiary of Adamis Pharmaceuticals, developed a compound to manage ulcers in horses, with a study of about 50 race horses showing endoscopic improvement as early as 14 days and clinical healing in over 95% of horses. A patent application has been filed, and two horses using the product won races at the 2017 Breeders Cup.